<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404764</url>
  </required_header>
  <id_info>
    <org_study_id>27245419.0.0000.5259</org_study_id>
    <nct_id>NCT04404764</nct_id>
  </id_info>
  <brief_title>Characterization of the Clinical-epidemiological Profile of Patients With SMA5q Types II and III: Observational Study</brief_title>
  <official_title>Characterization of the Clinical-epidemiological Profile of Patients With Spinal Muscular Atrophy (SMA) 5q Types II and III in Follow-up in the Brazilian Unified Public Health System: A Cross-sectional Observational Study (Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to characterize the clinical-epidemiological profile and baseline
      characteristics of patients with spinal muscular atrophy (SMA) 5q types II and III in
      follow-up at the Brazilian Unified Public Health System (SUS). The study data will be based
      on patients´ medical records from several Brazilian public hospitals, which will be defined
      by the Brazilian Ministry of Health (MS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective cross-sectional observational study to characterize the clinical and
      epidemiological profile of patients with spinal muscular atrophy (SMA) 5q types II and III,
      in follow-up at the Brazilian Unified Public Health System (SUS). This study aims to provide
      baseline data, which in the future may be used by the Brazilian Ministry of Health (MS) to
      assess the effectiveness of nusinersen, as recommended in a risk sharing agreement
      established between MS and the pharmaceutical company that produces Spiranza (nusinersen).
      The clinical and epidemiological data will be collected from patients´ medical records, such
      as the score for the Hammersmith Functional Motor Scale - Expanded (HFMSE) and the Revised
      Upper Limb Module (RULM) at baseline, the WHO motor milestones at baseline, disease duration,
      age at the time of disease diagnosis, age at the time of disease screening, SMN2 (gene copy
      number), history of hospitalizations, history and characterization of previous surgical
      procedures, treatment dosage used, patient caregiver´s profile (ie, a family member or
      companion, who is responsible for taking care of the patient for most of the time). Other
      variables of interest that will also be collected are patient´s age and gender, geographic
      distribution, attending physician expertise and care structure where the patients were
      treated. The data acquisition will be performed using a paper and eletronic CRF (Case report
      Form). Written informed consent will be obtained from patients who meet the study elegibility
      criteria. The study will be performed in Brazilian public hospitals (centers) that are able
      to provide the treatment with nusinersen under the SUS scope. The total sample of patients
      and number of participating centers will be defined by the MS - SCTIE (Secretariat of
      Science, Technology and Strategic Supplies)/ DECIT (Department of Science and Technology).
      However, the initial estimation is a sample of 100 patients to be included in 10-15 centers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Expanded Hammersmith Functional Motor Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Hammersmith Functional Motor Scale-Expanded (HFMSE) scores range from 0 to 66, with higher scores indicating better motor function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Revised Upper Limb Module</measure>
    <time_frame>In the inclusion of the study</time_frame>
    <description>Revised Upper Limb Module (RULM) scores range from 0 to 37, with higher scores indicating better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO motor milestones</measure>
    <time_frame>Unique evaluation at the time of inclusion</time_frame>
    <description>The six World Health Organization (WHO) motor milestones are sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone, and walking alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease duration</measure>
    <time_frame>At the time of inclusion in the study</time_frame>
    <description>Time between diagnosis and age at inclusion in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>Unique evaluation</time_frame>
    <description>SMN2 (gene copy number);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of hospitalizations</measure>
    <time_frame>Documented in the period prior to the inclusion of the study</time_frame>
    <description>Records of need for hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History and characterization of previous surgical procedures</measure>
    <time_frame>In the period prior to the inclusion of the study</time_frame>
    <description>History of comorbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment with nusinersen</measure>
    <time_frame>Registration of the dose used at the time of inclusion in the study</time_frame>
    <description>To undergo intrathecal administration of nusinersen at a dose of 12 mg</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Treated with nusinersen at SUS</arm_group_label>
    <description>Patients with Spinal Muscular Atrophy (SMA) 5q types II and III treated with nusinersen in the Brazilian Unified Public Health System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With indication to receive nusinersen at SUS</arm_group_label>
    <description>Patients with Spinal Muscular Atrophy (SMA) 5q types II and III with indication, but not yet receiving nusinersen treatment in the Brazilian Unified Public Health System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nusinersen Injectable Product</intervention_name>
    <description>The patient´s treatment is provided by SUS free of cost to the participant. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.</description>
    <arm_group_label>Treated with nusinersen at SUS</arm_group_label>
    <other_name>Spinraza</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Spinal Muscular Atrophy (SMA) 5q types II and III in follow-up in the
        Brazilian Unified Public Health System (SUS), undergoing treatment with nusinersen or not.
        For each patient included, a first-degree family member or companion responsible for taking
        care of the patient for most of the time will also be included, if they agree to
        participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patient Eligibility Criteria:

        Inclusion Criteria:

          -  Participants of both sexes, in any age group, who have a clinical diagnosis of SMA 5q
             type II or type III, in follow-up at SUS, undergoing treatment with nusinersen or not

          -  Clinical and molecular diagnosis of SMA 5q type II (disease started after 6 months of
             age), or Clinical and molecular diagnosis of SMA 5q type III (disease started after 18
             months of age)

        Exclusion Criteria:

          -  Refusal to provide written informed consent (either the patient or a legal
             representative)

          -  Symptom onset after 19 years of age

          -  Need for invasive ventilatory support for 16 hours or more per day for more than 21
             consecutive days

          -  Be participating or have participated in another clinical study aimed at specific
             treatment of SMA 5q other than with the drug nusinersen

          -  Having undergone treatment with gene therapy

        Caretaker Eligibility Criteria:

        Inclusion Criteria:

        • First-degree family member or companion responsible for taking care of the patient with
        clinical diagnosis of SMA 5q type II or type III

        Exclusion Criteria:

          -  Illiteracy

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otávio Berwanger, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanessa Teich, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edmar Zanoteli, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elice Batista, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Otávio Berwanger, PhD</last_name>
    <phone>1121511233</phone>
    <email>aro.pesquisa@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elice Batista, PhD</last_name>
    <phone>+55(11) 2151-5780</phone>
    <email>elice.batista@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal de Minas Gerais - Hospital das Clínicas</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juliana Gurgel Giannetti, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Juliana Gurgel Giannetti, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas da Universidade Estadual de Campinas - Unicamp</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcondes Cavalcante França Junior, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marcondes Cavalcante França Junior, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associação Hospitalar de Prot Infancia Dr Raul Carneiro - Hospital Infantil Pequeno Príncipe</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Banzzatto Ortega, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Adriana Banzzatto Ortega, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Dr. Albert Sabin</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André Luiz Santos Pessoa, PhD</last_name>
    </contact>
    <investigator>
      <last_name>André Luiz Santos Pessoa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paulo Dornelles Picon, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Paulo Dornelles Picon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonas Alex Morales Saute, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Pedro Ernesto</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Fritsch Toros Neves, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mario Fritsch Toros Neves, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raquel Tavares Boy da Silva, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heloisa Viscaino f. Souza Pereira, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura e Pediatria Martagão Gesteira da Universidade Federal do rio de Janeiro - UFRJ</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Prufer de Queiroz Campos Araujo, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra Prufer de Queiroz Campos Araujo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de São Paulo - HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edmar Zanoteli, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Edmar Zanoteli, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Acary Souza Bulle Oliveira, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Acary Souza Bulle Oliveira, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo Victor Sgobbi de Souza, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Israelita Albert Einstein</investigator_affiliation>
    <investigator_full_name>Otavio Berwanger</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>Spinal Muscular Atrophy type II</keyword>
  <keyword>Spinal Muscular Atrophy type III</keyword>
  <keyword>Mutation in SMN1</keyword>
  <keyword>Nusinersen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

